MDS Europe - Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y Leon

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y Leon (IECSCYL)

IBSAL (Institute of Biomedical Research of Salamanca) is a research centre that aims to improve translational research in medicine. The University Hospital of Salamanca is the nucleus of this Institute. It also includes research groups from the University Hospital, University of Salamanca and Consejo Superior de Investigaciones Científicas (Superior Council for Scientific Research) (IBMCC, IBFG, INCYL, USAL, CSIC) and IECSCYL, which is in charge of the financial & administrative management. The Haematology Department of the University Hospital in Salamanca, Spain is a reference centre for MDS diagnosis and treatment as well as for other haematological neoplasms. Salamanca Haematology Department has made significant contributions, above all in the fields of multiple myeloma, hematopoietic cell transplantation and MDS. It is a Centre of Excellence of the International MDS Foundation.

Our team

Prof. Consuelo del Cañizo, MD

Consuelo is one of the founders of the Spanish Group on Myelodysplastic Syndromes (GESMD) and has access to the data of patients in this group. She coordinates several GESMD activities and participates in the majority of them. The GESMD has made relevant contributions to knowledge about MDS and has one of the largest series of patients. Specifically, Consuelo has coordinated several of the recent publications of the GESMD. The Haematology Department of Salamanca has also provided relevant contributions to the Spanish Group of cytogenetic in MDS, as well as to research in the MDS-BM microenvironment. Consuelo participated in developing the Spanish MDS guidelines as well as the ‘Recommendations from the European Leukaemia Net for diagnosis and treatment of MDS’. In MDS-RIGHT she will be involved in the integration of longitudinal patterns of health care interventions and incorporation of epigenetics in these patterns and she will contribute to the quantification of health care resources associated with MDS.

Dr. María Diez-Campelo, MD PhD

María is a consultant physician and has a scientific background in diagnosis and management of MDS patients. She is involved in clinical and biological studies in MDS, data analyses and writing of scientific reports. Her core activities interests are diagnosis on MDS, cytomorphology and flow cytometry, prognosis and clinical management. She is one of the heads of the Spanish Group of Myelodysplastic Syndromes (GESMD) and has access to the data of patients in this group. She also coordinates several GESMD activities and participates in the majority of them. The GESMD has made relevant contributions to knowledge about MDS and has one of the largest series of patients. Specifically, María has participated in several of the recent publications of the GESMD. The Haematology Department of Salamanca has also provided relevant contributions to the Spanish Group of cytogenetic in MDS, as well as to research in the MDS-BM microenvironment. María participated in developing the Spanish MDS guidelines. In MDS-RIGHT she will be involved in the integration of longitudinal patterns of health care interventions and incorporation of epigenetics in these patterns and she will contribute to the quantification of health care resources associated with MDS.

Dr. Jesus Hernández-Rivas, MD PhD

Jesus is a consultant physician and director of the molecular genetics and sequencing unit of the Center of Cancer research of the University of Salamanca. Jesus has been involved in several european NGS projects such as IRON (Phase I and II), NGS/PTL and the CLL consortium (IGCG). He is mainly involved in MDS, CLL and ALL.

Dr. María Abaigar

María is a research fellow, with a background in the molecular characterization of MDS. She has just finished her PhD entitled "Molecular Characterization of Myelodysplastic Syndromes (MDS): Analysis of genomic abnormalities in the development of MDS progression to Acute myeloblastic Leukemia and response to treatment with 5-Azacytidine”. Her research focuses on the application of genome-wide high-throughput techniques, such as genomic arrays, gene expression profiling and next-generation sequencing (NGS), in the study of MDS. She is a member or the Spanish Group on MDS (GESMD) and she has actively participated in the European projects: EuGESMA, IRON-II and NGS-PTL. In MDS-RIGHT she will be involved in the integration of molecular data of MDS patients.

Dr. Mercedes Sanchez-Barba, MSc

Mercedes, graduated in Science (Mathematics section). She is a teacher in the Statistics Department at the University of Salamanca. She obtained her PhD in the department of Statistics in the University of Salamanca in 2008 and an Extraordinary Award of the Master in Advanced Multivariate Data Analysis in 2013. Her main research areas are the application of statistical, multivariate methods to different fields such as Medicine, Biology or Computing. She has completed a 22 - month stay in the Spanish Clinical Trials Platform (CAIBER) in the University Hospital of Salamanca, financed by the Carlos III Health Institute. She has published more than 20 scientific articles in national and/or international journals s and she has presented more than 40 conferences in national and international Congress. She has directed three doctoral thesis and eight Final Master’s Thesis. She has received seven research awards, from which an award to the best clinical publishing about hematopoietic parental transplant (TPH) can be highlighted. She has actively attended eight research projects, most of them related to Medicine.

Dr Félix López Cadenas, MD

Félix López Cadenas is a consultant hematologist at University Hospital of Salamanca. Since he completed his residency in Hematology (June 2017) he focused his professional activity in the area of hematological diagnosis (mainly cytomorphology) and clinical management of myeloid malignancies. He has participated in numerous clinical and biological studies, most of them related to myelodysplastic syndromes. He is a member of the European Hematology Association (EHA), Spanish Hematology Association (SEHH), and Spanish Group of Myelodysplastic Syndromes (GESMD) among others. Specifically, Félix López has participated in several of the recent publications of the GESMD including his participation in the elaboration of the Spanish guidelines for the management and diagnosis of myelodysplastic syndromes that will be published throughout this year.

Login